David Gemperline

David Gemperline is the Director of Bioinformatics at Eli Lilly and Company, bringing 8 years of experience in the pharmaceutical industry. They have successfully developed production-grade algorithms for label-free quantitative proteomics and have derived insights from human clinical trials in the autoimmune field. David has a strong background in analyzing human samples, including single-cell RNA sequencing and mass spectrometry-based metabolomics. They earned a B.A. in Biology and Chemistry from Carthage College and a PhD in Genetics from the University of Wisconsin-Madison.